Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
April 30, 2007

Pro-Pharmaceuticals and Digna to Enhance Hep C Therapeutics

  • Pro-Pharmaceuticals will apply its carbohydrate technology platform to Digna Biotech’s drugs to achieve improved treatment of chronic hepatitis C infections.

    "The collaboration with Digna is an important step in the development, commercialization, and validation of our first-in-class carbohydrate technology," notes David Platt, Ph.D., president and CEO, Pro-Pharmaceuticals.

    Pro-Pharmaceuticals' Davanat® will be the first to be checked as data from preclinical and clinical trials show that Davanat increased the patient's exposure to 5-FU 10-fold with no increase in toxicity.

  • You’re all set! Thank you for subscribing to GEN Highlights.